Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNITUDE
2012-003463-22Phase 3Suspended
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of peginterferon lambda-1a, ribavirin, daclatasvir in hepatitis C virus infection, sponsored by Bristol Myers Squibb. Started Jan 2013; status: suspended.
02
Drugs
peginterferon lambda-1aribavirindaclatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2012-003463-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003463-22.